Zollinger-Ellison syndrome: Classical considerations and current controversies

Oncologist

Volumn 19, Issue 1, 2014, Pages 44-50

  Epelboym, Irene ^a   Mazeh, Haggi ^b  

^a NewYork Presbyterian Hospital   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Gastric acid; Gastrinoma; Multiple endocrine neoplasia type 1; Peptic ulcer

Indexed keywords

GASTRIC ACID; GASTRINOMA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PEPTIC ULCER;

GASTRINOMA; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; ZOLLINGER-ELLISON SYNDROME;

EID: 84892566023     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0369     Document Type: Article

References (76)

1. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955; 142: 709-723; discussion 724-728.
2. Hou W, Schubert ML. Gastric secretion. Curr Opin Gastroenterol 2006; 22: 593-598.
3. McGuigan JE, Wolfe MM. Secretin injection test in the diagnosis of gastrinoma. Gastroenterology 1980; 79: 1324-1331.
4. Thakker RV, Newey PJ, Walls GV et al. Clinical practice guidelines formultiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97: 2990-3011.
5. Berna MJ, Hoffmann KM, Serrano J et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine 2006; 85: 295-330.
6. Eriksson B, Oberg K, Skogseid B. Neuroendocrine pancreatic tumors: Clinical findings in a prospective study of 84 patients. Acta Oncol 1989; 28: 373-377.
7. Stage JG, Stadil F. The clinical diagnosis of the Zollinger-Ellison syndrome. Scand J Gastroenterol Suppl 1979; 53: 79-91.
8. Sheppard BC, Norton JA, Doppman JL et al. Management of islet cell tumors in patients with multiple endocrine neoplasia: A prospective study. Surgery 1989; 106: 1108-1117; discussion 1117-1118.
9. Richardson CT, Peters MN, Feldman M et al. Treatment of Zollinger-Ellison syndrome with exploratory laparotomy, proximal gastric vagotomy, and H2-receptor antagonists: A prospective study. Gastroenterology 1985; 89: 357-367.
10. Norton JA. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg 1994; 31: 77-156.
11. Rindi G, Arnold R, Bosman FT et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman TFCF, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: InternationalAgency forResearchonCancer (IARC), 2010: 13.
12. O'Toole D, Delle Fave G, Jensen RT. Gastric and duodenal neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012; 26: 719-735.
13. Deveney CW, Deveney KE. Zollinger-Ellison syndrome (gastrinoma): Current diagnosis and treatment. Surg Clin North Am 1987; 67: 411-422.
14. Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 1995; 46: 395-411.
15. Jensen RT, Gardner JD. Zollinger-Ellison syndrome: clinical presentation, pathology, diagnosis and treatment. InADannenberg, DZakim, eds. Peptic Ulcer and Other Acid-Related Diseases. New York NY: Academic Research Association, 1991: 117-211.
16. Rehfeld JF, Bardram L, Hilsted L et al. Pitfalls in diagnostic gastrin measurements. Clin Chem 2012; 58: 831-836.
17. Frucht H, Howard JM, Slaff JI et al. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome: A prospective study. Ann Intern Med 1989; 111: 713-722.
18. Gibril F, Jensen RT. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours. Dig Liver Dis 2004; 36 (suppl 1): S106-S120.
19. Mignon M, Ruszniewski P, Podevin P et al. Currentapproachto themanagementofgastrinoma and insulinoma in adults with multiple endocrine neoplasia type I. World J Surg 1993; 17: 489-497.
20. Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: Clinical features, diagnosis and medical treatment: Advances. Best Pract Res Clin Gastroenterol 2012; 26: 737-753.
21. Norton JA, Fraker DL, Alexander HR et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 635-644.
22. Norton JA, Fraker DL, Alexander HR et al. Surgery increases survival in patients with gastrinoma. Ann Surg 2006; 244: 410-419.
23. Gualdi GF, Casciani E, Polettini E. Imaging of neuroendocrine tumors [in Italian]. Clin Ter 2001; 152: 107-121.
24. Gibril F, Jensen RT. Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors. Yale J Biol Med 1997; 70: 509-522.
25. Krudy AG, Doppman JL, Jensen RT et al. Localization of islet cell tumors by dynamic CT: Comparison with plain CT, arteriography, sonography, and venous sampling. AJR Am J Roentgenol 1984; 143: 585-589.
26. Alexander HR, Fraker DL, Norton JA et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228: 228-238.
27. Norton JA, Jensen RT. Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasiatype 1 (MEN1). Surg Oncol 2003; 12: 145-151.
28. Klose KJ, Heverhagen JT. Localisation and staging of gastrin producing tumours using crosssectional imaging modalities. WienKlinWochenschr 2007; 119: 588-592.
29. Gibril F, Reynolds JC, Doppman JL et al. Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: A prospective study. AnnInternMed1996; 125: 26-34.
30. Ruszniewski P, Amouyal P, Amouyal G et al. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 1995; 117: 629-635.
31. Maton PN, Miller DL, Doppman JL et al. Role of selective angiography in the management of patients with Zollinger-Ellison syndrome. Gastroenterology 1987; 92: 913-918.
32. Thom AK, Norton JA, Doppman JL et al. Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery 1992; 112: 1002-1008; discussion 1008-1009.
33. Gibril F, Doppman JL, Chang R et al. Metastatic gastrinomas: Localization with selective arterial injection of secretin. Radiology 1996; 198: 77-84.
34. Ito T, Igarashi H, Uehara H et al. Pharmacotherapy of Zollinger-Ellison syndrome. Expert Opin Pharmacother 2013; 14: 307-321.
35. Banasch M, Schmitz F. Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors. WienKlinWochenschr 2007; 119: 573-578.
36. Jensen RT. Consequences of long-term proton pump blockade: Insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006; 98: 4-19.
37. Norton JA. Surgical treatment and prognosis of gastrinoma. Best Pract Res Clin Gastroenterol 2005; 19: 799-805.
38. Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: A comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg 2009; 46: 13-106.
39. Jensen RT, Niederle B, Mitry E et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84: 173-182.
40. Gibril F, Jensen RT. Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep 2005; 7: 114-121.
41. Norton JA, Fang TD, Jensen RT. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Canc Netw 2006; 4: 148-153.
42. Norton JA, Alexander HR, Fraker DL et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001; 234: 495-505; discussion 505-506.
43. MacFarlane MP, Fraker DL, Alexander HR et al. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery 1995; 118: 973-979; discussion 979-980.
44. Norton JA, Jensen RT. Resolvedand unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004; 240: 757-773.
45. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: Pancreatic endocrine tumors. Gastroenterology 2008; 135: 1469-1492.
46. Jensen RT, Cadiot G, Brandi ML et al. ENETS Consensus Guidelines for themanagement of patients with digestive neuroendocrine neoplasms: Functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 98-119.
47. Jensen RT, Berna MJ, Bingham DB et al. Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008; 113: 1807-1843.
48. Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998; 243: 477-488.
49. Sawicki MP, Howard TJ, Dalton M et al. The dichotomous distribution of gastrinomas. Arch Surg 1990; 125: 1584-1587.
50. Stabile BE, Morrow DJ, Passaro E Jr. The gastrinoma triangle: Operative implications. Am J Surg 1984; 147: 25-31.
51. DiNorcia J, Ahmed L, Lee MK et al. Better preservation of endocrine function after central versus distal pancreatectomy for mid-gland lesions. Surgery 2010; 148: 1247-1254; discussion 1254-1256.
52. Grozinsky-Glasberg S, Barak D, Fraenkel M et al. Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer 2011; 117: 1377-1385.
53. Shojamanesh H, Gibril F, Louie A et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002; 94: 331-343.
54. Gut P, Fischbach J, Kamiński G et al. Contemporary methods of therapy and follow-up of neuroendocrine tumours of the gastrointestinal tractand the pancreas. ContempOncol (Pozn) 2012; 16: 371-375.
55. Clouse ME, Perry L, Stuart K et al. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 1994; 55 (suppl 3): 92-97.
56. Jaskowiak NT, Fraker DL, Alexander HR et al. Is reoperation for gastrinoma excision indicated in Zollinger-Ellison syndrome? Surgery 1996; 120: 1055-1062; discussion 1062-1063.
57. Grobmyer SR, Vogel SB, McGuigan JE et al. Reoperative surgery in sporadic Zollinger-Ellison syndrome: Longterm results. J Am Coll Surg 2009; 208: 718-722; discussion 722-724.
58. Jensen RT. Carcinoid and pancreatic endocrine tumors: Recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol 2000; 12: 368-377.
59. Norton JA, Jensen RT. Unresolvedsurgical issues in the management of patients with Zollinger-Ellison syndrome. World J Surg 1991; 15: 151-159.
60. Fishbeyn VA, Norton JA, Benya RV et al. Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: The best approach. Ann Intern Med 1993; 119: 199-206.
61. Mortellaro VE, Hochwald SN, McGuigan JE et al. Long-term results of a selective surgical approach to management of Zollinger-Ellison syndrome in patients with MEN-1. Am Surg 2009; 75: 730-733.
62. Ellison EC, Sparks J, Verducci JS et al. 50-year appraisalofgastrinoma: Recommendationsforstaging and treatment. J Am Coll Surg 2006; 202: 897-905.
63. NCCN Clinical Practice Guidelines. Available at http://www. nccn. org/professionals/physician_gls/ f_guidelines. asp#neuroendocrine. Accessed September 10, 2013.
64. DiNorcia J, Lee MK, Reavey PL et al. One hundred thirty resections for pancreatic neuroendocrine tumor: Evaluating the impact of minimally invasive and parenchyma-sparing techniques. J Gastrointest Surg 2010; 14: 1536-1546.
65. Atalar K, Warren OJ, Jacyna M et al. Laparoscopic resection for primary lymph node gastrinoma. Pancreas 2013; 42: 723-725.
66. Min BH, Kim ER, Lee JH et al. Management strategy for small duodenal carcinoid tumors: Does conservative management with close follow-up represent an alternative to endoscopic treatment? Digestion 2013; 87: 247-253.
67. Blanc P, Porcheron J, Pages A et al. Laparoscopic excision of a duodenal neuroendocrine tumor [in French]. Ann Chir 2000; 125: 176-178.
68. Lopez CL, Waldmann J, Fendrich V et al. Longterm results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1. Langenbecks Arch Surg 2011; 396: 1187-1196.
69. Tonelli F, Fratini G, Nesi G et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 2006; 244: 61-70.
70. Giudici F, Nesi G, Brandi ML et al. Surgical management of insulinomas in multiple endocrine neoplasia type 1. Pancreas 2012; 41: 547-553.
71. Cherner JA, Sawyers JL. Benefit of resection of metastatic gastrinoma inmultiple endocrine neoplasia type I. Gastroenterology 1992; 102: 1049-1053.
72. Partensky C, Berger F, Owono P et al. Cephalic duodenopancreatectomy for endocrine tumor of the ampulla of Vater and of the minor papilla [in French]. Gastroenterol Clin Biol 1999; 23: 832-836.
73. Sarmiento JM, Farnell MB, Que FG et al. Pancreaticoduodenectomy for islet cell tumors of the head of the pancreas: Long-term survival analysis. World J Surg 2002; 26: 1267-1271.
74. Pisegna JR, Norton JA, Slimak GG et al. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992; 102: 767-778.
75. Pachera S, Yokoyama Y, Nishio H et al. A rare surgical case of multiple liver resections for recurrent liver metastases from pancreatic gastrinoma: Liver and vena cava resection. JHepatobiliary Pancreat Surg 2009; 16: 692-698.
76. Norton JA, Kivlen M, Li M et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003; 138: 859-866.